Alfa Wassermann SpA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Alfa Wassermann SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011845
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alfa Wassermann SpA (Alfa Wassermann), a subsidiary of AlfaSigma SpA is a pharmaceutical company which produces and distributes drugs for human health. The company provides new discoveries in medicine, biology and genomics. Alfa Wassermann finds solutions for paradox treatment. The company offers self meditation products for sore throat, headaches, and muscle and joint pain treatments. It also provides antibiotics used for treatment of diseases such as vascular diseases, deep venous thrombosis and gastrointestinal tract diseases. Alfa Wassermann operates through its offices located in the US, the Netherlands, Mexico, France, Spain, Portugal, China, Poland, Romania, Tunisia and Slovakia. Alfa Wassermann is headquartered in Bologna, Italy.

Alfa Wassermann SpA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alfa Wassermann SpA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Alfa Wassermann SpA, Medical Devices Deals, 2011 to YTD 2017 9
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Alfa Wassermann Acquires Italian Operations from Sigma-Tau 12
Partnerships 14
Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 14
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 16
European Institute of Oncology Enters Into Co-Development Agreement With Sigma Tau Industrie 17
Theravance Enters Into Co-Development Agreement With Alfa Wassermann For Velusetrag 18
a V.I. Pharma Enters into Distribution Agreement with Sigma-Tau for Eurartesim 19
Ezose Sciences Enters Into R&D Agreement With Sigma-Tau Industrie Farmaceutiche 20
Licensing Agreements 21
CVie Therapeutics Enters into Licensing Agreement with Sigma-Tau Industrie 21
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 22
Sigma-Tau Pharma Enters into Licensing Agreement with Crosscare for Colief 23
Lee’s Pharma HK Enters into Licensing Agreement with Sigma-Tau Industrie Farmaceutiche Riunite 24
CVie Therapeutics to Enter into Licensing Agreement with Sigma-Tau 25
CVie Therapeutics to Enter into Licensing Agreement with RostaQuo 27
Soligenix Expands Licensing Agreement With Sigma-Tau Pharma For orBec 29
Equity Offering 31
RegeneRx BioPharma Completes Registered Direct Offering Of US$1.45 Million 31
Asset Transactions 33
Alfa Wassermann Acquires Italian Operations from Sigma-Tau 33
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 34
Acquisition 36
Sigma-Tau May Sell Sigma-Tau Pharma 36
Alfa Wassermann Acquires Promefarm 37
Alfa Wassermann SpA – Key Competitors 38
Alfa Wassermann SpA – Key Employees 39
Alfa Wassermann SpA – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Key Facts 2
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alfa Wassermann SpA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alfa Wassermann SpA, Deals By Therapy Area, 2011 to YTD 2017 8
Alfa Wassermann SpA, Medical Devices Deals, 2011 to YTD 2017 9
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alfa Wassermann Acquires Italian Operations from Sigma-Tau 12
Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 14
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 16
European Institute of Oncology Enters Into Co-Development Agreement With Sigma Tau Industrie 17
Theravance Enters Into Co-Development Agreement With Alfa Wassermann For Velusetrag 18
a V.I. Pharma Enters into Distribution Agreement with Sigma-Tau for Eurartesim 19
Ezose Sciences Enters Into R&D Agreement With Sigma-Tau Industrie Farmaceutiche 20
CVie Therapeutics Enters into Licensing Agreement with Sigma-Tau Industrie 21
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 22
Sigma-Tau Pharma Enters into Licensing Agreement with Crosscare for Colief 23
Lee’s Pharma HK Enters into Licensing Agreement with Sigma-Tau Industrie Farmaceutiche Riunite 24
CVie Therapeutics to Enter into Licensing Agreement with Sigma-Tau 25
CVie Therapeutics to Enter into Licensing Agreement with RostaQuo 27
Soligenix Expands Licensing Agreement With Sigma-Tau Pharma For orBec 29
RegeneRx BioPharma Completes Registered Direct Offering Of US$1.45 Million 31
Alfa Wassermann Acquires Italian Operations from Sigma-Tau 33
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 34
Sigma-Tau May Sell Sigma-Tau Pharma 36
Alfa Wassermann Acquires Promefarm 37
Alfa Wassermann SpA, Key Competitors 38
Alfa Wassermann SpA, Key Employees 39
Alfa Wassermann SpA, Other Locations 40
Alfa Wassermann SpA, Subsidiaries 40

★海外企業調査レポート[Alfa Wassermann SpA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■

◆H&Iグローバルリサーチ株式会社のお客様(例)◆